GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Healius Ltd (OTCPK:PHCRF) » Definitions » 9-Day RSI

PHCRF (Healius) 9-Day RSI : N/A (As of Jan. 19, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Healius 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2025-01-19), Healius's 9-Day RSI is N/A.

The industry rank for Healius's 9-Day RSI or its related term are showing as below:

PHCRF's 9-Day RSI is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 44.57
* Ranked among companies with meaningful 9-Day RSI only.

Competitive Comparison of Healius's 9-Day RSI

For the Diagnostics & Research subindustry, Healius's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healius's 9-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Healius's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Healius's 9-Day RSI falls into.



Healius  (OTCPK:PHCRF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healius  (OTCPK:PHCRF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Healius 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Healius's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Healius Business Description

Traded in Other Exchanges
Address
161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.

Healius Headlines

From GuruFocus

Half Year 2024 Healius Ltd Earnings Call Transcript

By GuruFocus Research 02-28-2024

David Herro Comments on Healius

By Sydnee Gatewood Sydnee Gatewood 01-09-2020

Half Year 2023 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

Healius Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 03-29-2024

Full Year 2022 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

Healius Ltd Conference Call Transcript

By GuruFocus Research 03-29-2024

David Herro Comments on Primary Health Care

By Holly LaFon Holly LaFon 04-11-2016

Half Year 2022 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024